vorasidenib
servier
['vorasidenib']
after vorasidenib data presented in nejm/asco. how would you proceed for this hypothetical case: 43 yo pt with newly diagnosed who grade 2 idh-mutant astrocytoma with residual disease following resection feel free to share any discussion points in comments!
neuro-oncology 🧠 @ Emory — Working towards a better future for patients with CNS malignancies